You are here

Janssen Requests Approval of Golimumab for Treatment of Ulcerative Colitis

Approximately 700,000 people in the U.S. are affected by UC, a chronic inflammatory bowel disease marked by inflammation and ulceration of the lining (mucosa) of the colon, which may lead to bloody stools, severe diarrhea, and frequent abdominal pain.

The U.S. application is supported by efficacy and safety findings from the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment (PURSUIT), which included phase III multicenter, randomized, double-blind, placebo-controlled studies designed to evaluate the safety and efficacy of subcutaneous induction and every-4-week maintenance regimens of Simponi in adults with moderate to severe UC.

Simponi is a human monoclonal antibody that targets and neutralizes excess TNF-alpha, a protein that can cause inflammation and damage to bones, cartilage, and tissue when overproduced in the body in response to inflammatory disease. Simponi is approved in 52 countries, including the U.S., for rheumatologic disorders.

More information can be found on the Sacramento Bee's Web site.

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring